Close Menu

CAR therapies

The company has used its semi-closed electroporation system to manufacture autologous CAR T cells to treat ovarian cancer and leukemia patients in two trials.

The company's T-cell product, PRIME IL-15, which is loaded with an IL-15fc nanogel, led 10 out of 17 advanced solid tumor patients to have stable disease.

The agency ordered Poseida to halt the trial in August after a patient died but is now allowing the company to resume the study with an amended protocol.

The results demonstrated the safety and preliminary efficacy of bispecific, anti-CD19, anti-CD20 CAR T-cell therapy for patients with B-cell cancers.

The study identified multiple clusters of engineered natural killer T cells based on RNA-seq and found that they could be effective against the disease.

Patients in the Phase II trial will receive infusions of autologous T cells that have been genetically engineered to remove the intracellular checkpoint CISH.

The companies will combine Neogene's expertise in targeting tumor neoantigens with Twist's DNA synthesis platform and product lines.

The Phase I/II trial will assess the safety, recommended dose, initial efficacy, and pharmacokinetics of the autologous T-cell therapy ET140203 Artemis.

Researchers have identified unique features associated with the degree to which LBCL patients respond to and experience toxicity with Yescarta.

The Phase I/II trial will assess the safety and efficacy of the CAR T cell therapy MB-102 for patients with three types of hematologic malignancies.